Brixton Biosciences: FDA filings under this applicant name
FDA lists 0 510(k) clearances under the applicant name “Brixton Biosciences”, plus 1 De Novo decision, across 1 product code in 1 review panel. Related companies, subsidiaries and acquired businesses that file under other applicant names are counted on their own pages, not here.
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| SJA | Injectable For Thermal Treatment Of Musculoskeletal Pain | 1 | 0 |
Review panels
- Orthopedic (1)
PMA and De Novo decisions
| Number | Pathway | Device | Decision date |
|---|---|---|---|
| DEN250067 | De Novo | Injectable For Thermal Treatment Of Musculoskeletal Pain | 2026-08-21 |
Recalls
openFDA lists no recalls under a recalling firm named Brixton Biosciences.
Recalling firms are matched to this applicant name by name only (same normalization), so related entities that recall under another name are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
Device clinical trials
An industry sponsor named Brixton Biosciences is the lead sponsor of 1 device studies on ClinicalTrials.gov (1 active or recruiting). Most recent:
- NCT06700109: INJECTABLE COLD ENERGY THERAPY FOR THE MANAGEMENT OF CHRONIC PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE (Active not recruiting, started 2024-11-19)
Frequently asked questions
How many FDA 510(k) clearances are listed under Brixton Biosciences?
FDA lists 0 510(k) clearances under the applicant name “Brixton Biosciences”, plus 1 De Novo decision, across 1 product code in 1 review panel. Filings under other applicant names, such as subsidiaries, are not included.
Which FDA product codes appear under Brixton Biosciences?
The most frequent FDA product codes under this applicant name are SJA (Injectable For Thermal Treatment Of Musculoskeletal Pain, 1).
Next steps
- See all 0 Brixton Biosciences clearances with predicates and recalls
- Run predicate analysis for product code SJA, Brixton Biosciences's most frequent
Data from openFDA (510(k), PMA, De Novo, device recalls), ClinicalTrials.gov and SEC company tickers. Each page covers one FDA applicant name, with punctuation and legal suffixes removed; filings under other names are not included. Review days run from FDA receipt to decision. Not regulatory advice. Report an error in this data.